Searched for
ANTIDIABETIC DRUG MARKET
These large- and mid-cap stocks may give more than 25% return in 1 year, according to analystsFor the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...- For both the compulsive trader and careful investor: 25 stocks to watch if risk appetite returns; some with upside potential, some notIf the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- Alkem Labs CEO Vikas Gupta may exit companyAlkem Labs, a leading Indian drug maker, is set for a top management change. Vikas Gupta, the CEO for nearly three years, is expected to de...
- Dr Reddy's gets nod to roll out generic oral semaglutide drug"The formulation was clinically evaluated in a head-to-head comparative study conducted in India, which established the non-inferiority to ...
- Generics of MSD diabetes pill set to flood market as patent expiresAccording to market research firm AIOCD, at least 50 Indian drug makers are jumping into the fray with around 100 generic versions of the p...
- Cipla to market Novartis, and J&J’s products, while Alkem partners Dong A of South KoreaAlkem is bringing in a fresh brand. Evogliptin has been approved in South Korea and the company is waiting for an approval from the USFDA a...
- Zydus Cadila's anti-diabetic drug gets USFDA marketing nodThe group now has nearly 120 approvals from the USFDA and so far filed 300 abbreviated new drug applications (ANDAs), Cadila Healthcare sai...
- Sun Pharma, AstraZeneca tie up to sell latest anti-diabetes drug DapagliflozinDiabetes estimated to affect approximately 69.2 million people in India and more than 415 million people worldwide.
- Zydus Cadila gets USFDA nod for anti-diabetics tabletsDrug firm Zydus Cadila has received final nod from the US health regulator to sell anti-diabetics Glyburide and Metformin Hcl tablets in th...
- Mankind pharma joins the anti-diabetic drug warIndia's anti-diabetic market is one of the fastest growing therapy segments, with a growth exceeding 25% at Rs 7638 crore, according to the...
- Cadila crashes the gliptin market with 'most affordable anti diabetic drug'Tenglyn, is a product belonging to a new class of drugs called gliptins, a segment that has witnessed the most aggressive growth among all ...
- High Court restrains Glenmark Pharmaceuticals from business of anti-diabetes drugsEarlier, in an interim order, a division bench of the high Court had restrained Glenmark from making or selling its drug, used for treatmen...
- Boehringer Igelheim aims for top slot with anti-diabetes drug launchWith Jardiance, BI has the advantage of significantly reducing cardiovascular risks associated with most patients with diabetes.
- Anti-diabetic drug tops India's pharma salesIn a grim reminder of the rise of lifestyle diseases, anti-diabetic molecule has for the first time become the largest-selling formulation ...
- MSD-Glenmark drug patent row: Delhi High Court reserves verdictThe Delhi High Court today reserved its verdict on US drug major Merck Sharp and Dohme's appeal against a single judge bench order.
- Patent row: Delhi High Court refuses interim relief to US drug firm MerckThe court's order came on MSD's plea alleging that the Indian pharma company has violated its intellectual property right (IPR) over its an...
- Patent row: Delhi High Court refuses interim relief to US drug firm MerckThe development assumes significance as on Monday the Supreme Court had rejected the plea of Novartis AG for patent protection of its anti-...
- Zydus files IND application with DCGI for diabetes and obesityHealthcare major, Zydus Cadila has filed IND (Investigational New Drug) application for anti-diabetic and anti-obesity drug with Drugs Cont...
Load More
